Tagrisso, Chemo Combo Shows Promise in Lung Cancer Trial

(Reuters) – The combination of AstraZeneca’s cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday.

The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso.

The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

“Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing,” Susan Galbraith, executive vice president of AstraZeneca’s oncology R&D division said in a statement.

Analysts at Barclays have already flagged the threat of potential competition, especially with Johnson & Johnson running a head-to-head trial with its own drug, Rybrevant.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Savio D’Souza)

Source: Read Full Article

Related posts:
  1. ‘I Thought I Was A Lazy, Depressed College Student. Then I Was Diagnosed With Narcolepsy’
  2. Study highlights the importance of ensuring newborns have close contact with parents during COVID-19
  3. Rhode Island AG opens investigation into UnitedHealthCare after data breach
  4. Severe respiratory infections linked to some congenital cardiovascular defects
Health News Comments Off on Tagrisso, Chemo Combo Shows Promise in Lung Cancer Trial